COMPANY

ALZpath, Inc.

“The ALZpath antibody is being used to deliver early and accurate detection of Alzheimer’s disease pathology through a simple blood test.” Source · checked Oct 13, 2026

Keywords: Alzheimer's Alzheimer’s antibody pTau217 Diagnostics monoclonal antibody

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 13, 2026

1 sourcedFunding itemssee sources below

Sourced facts

Each item links to its source and was checked by an independent review on Oct 13, 2026 (San Diego batch).

Therapeutic areas or services

Alzheimer's · alzpath.bio · checked Oct 13, 2026
Alzheimer’s · alzpath.bio · checked Oct 13, 2026
pTau217 · alzpath.bio · checked Oct 13, 2026

Focus / stage (company wording)

Alzheimer · alzpath.bio · checked Oct 13, 2026

Headquarters address

Carlsbad, CA · sec.gov · checked Oct 13, 2026

Funding (company or press release)

Total Amount Sold $ 8,411,219 · sec.gov · checked Oct 13, 2026

Funding and NIH signals

SEC Form D raise Raised $8.41M (Form D filed Jul 21, 2026). SEC Form D 0002145244-26-000001 (Jul 21, 2026)
Evidence (1 event)
- Jul 21, 2026 · SEC Form D 0002145244-26-000001
  Name of Issuer: ALZpath, Inc.; CIK: 2145244; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-07-21; Industry Group: Biotechnology; Date of First Sale: 2026-07-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10411219; Total Amount Sold: 8411219; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Deal Roche deal · amount not disclosed · announced Jun 10, 2024 Company release ↗
Source quote
- Jun 10, 2024 · Company release ↗
  “(ALZpath), a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced a strategic license”

From the company’s own releases; this list is partial. All raises and deals